SUBSCRIBE
SUBSCRIBE
News   Deals

CSL Limited Says U.S. Regulator May Block Talecris Biotherapeutics Deal

May 26, 2009 | 
1 min read

Bookmark and Share

Reuters -- U.S. Federal Trade Commission officials are opposed to Australian biotech firm CSL Ltd’s planned $3.1 billion purchase of smaller U.S. rival Talecris Biotherapeutics Holdings Corp, CSL said on Monday.

Mergers & acquisitions
MORE ON THIS TOPIC
Podcasts
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
March 19, 2025
 · 
2 min read
 · 
Heather McKenzie
A big businessman hands over the key to the house. Art collage, hand with keys.
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
March 17, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
AstraZeneca's sign on its office in California
Mergers & acquisitions
AstraZeneca Makes Potential $1B Cell Therapy Play in EsoBiotec Buy
March 17, 2025
 · 
2 min read
 · 
Tristan Manalac
piggy bank behind umbrella to cover and protect from downturn arrow. Protection or defensive stock in economy crisis
Mergers & acquisitions
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
March 13, 2025
 · 
1 min read
 · 
Dan Samorodnitsky